Skip to main content

Posts

Showing posts from January, 2011

VS Ramachandran

From The Observer VS Ramachandran: The Marco Polo of neuroscience Among his contemporaries he's a pioneer who, by using real mirrors and looking at mirror neurons, is changing the way we think about thinking Andrew Anthony The Observer Sunday, 30 January 2011 Read the article

In The Wide World: Houston, Texas

The website of Houston's TIRR rehabilitation center, lately in the news: The Institute for Rehabilitation and Research From the homepage: "TIRR treats people with a range of disabilities from complex conditions like brain injury, stroke, spinal cord injury, multiple trauma and amputation, to rehabilitation for conditions including multiple sclerosis, Parkinson’s disease, post-polio syndrome, rheumatoid arthritis and lupus." Here is a sample newsletter: Summer 2010

Olfaction

From The Independent : The smelling test: The genetics of olfaction Why are some people more sensitive to odours than others? And why do no two people experience a scent in the same way? The answer lies in our genes, explains Laura Spinney 24 January 2011 read the article

Student Resource: ClinicalTrials.gov

If you are just learning your way around disorders of the brain and the central nervous system, topics that likely would be of interest to you are how these conditions are treated and what current research is being performed to seek out new treatments. For pharmaceutical research, you can determine the current clinical-trials environment with a resource like ClinicalTrials.gov . The best way to use this resource is to learn about the Advanced Search option. Begin by playing with different methods of using the advanced search, such as by medical condition or age group. Look for broad results but then use several different parameters to focus in on very specific results. It, alongside other great resources such as PubMed, can be part of your approach to keeping up to date in those areas of neuropsychology that are of interest to you.

FDA: PCNS Drugs Advisory Committee Results for Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent

A fuller report from The New York Times : F.D.A. Sees Promise in Alzheimer’s Imaging Drug By GINA KOLATA The New York Times Published: January 20, 2011 "A committee voted that the agency should approve the first test that can show the characteristic plaques of Alzheimer’s disease in the brain of a living person." Read the full article

FDA: PCNS Drugs Advisory Committee Results for Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent

From The New York Times : F.D.A. Sees Promise in Alzheimer’s Imaging Drug By THE ASSOCIATED PRESS Published: January 20, 2011 Filed at 5:40 p.m. EST WASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical designed to help screen for Alzheimer's disease could be useful pending additional study and training for physicians. The Food and Drug Administration panel of advisers voted 16-0 in favor of approval for Eli Lilly's Amyvid on the condition that the company demonstrates the images can be consistently interpreted by physicians who have received training in reading the scans. Without those requirements the panel voted 13-3 against approval for the injection in an earlier vote. The FDA is not required to follow the panel's advice, though it often does. Read the full report

Upcoming: Alzheimer's: FDA Advisory Committee Meeting (20-21 January 2011)

From the FDA (.pdfs of briefing material is available at the link below): January 20-21, 2011: Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement Read the full announcement Agenda "On January 20, 2011, the committee will discuss new drug application (NDA) 202-008, florbetapir F 18 injection, sponsored by Avid Radiopharmaceuticals, Inc. , proposed for use in positron emission tomography (PET) imaging of β-amyloid (beta-amyloid) aggregates in the brain to help rule out Alzheimer's disease. "On January 21, 2011, the committee will discuss NDA 201-277, gadobutrol injection, sponsored by Bayer HealthCare Pharmaceuticals, proposed for use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity (abnormal blood supply and circulation) of the central nervous system. The BBB is an area consisting of specialized ...

Alzheimer's Products

From The New York Times : Tests Show Promise for Early Diagnosis of Alzheimer’s By GINA KOLATA The New York Times Published: January 18, 2011 "Researchers report major advances on two vexing questions about Alzheimer’s: How do you know if someone who is demented has it? And how can you screen the general population for risk?" Read the full article. The report includes discussion about this week's forthcoming FDA Advisory Committee discussion about Avid Radiopharmaceuticals product.

Upcoming Event: British Psychological Society (4-6 May 2011, Glasgow)

The Annual Conference of the British Psychological Society (BPS) takes place in early May in Glasgow. The conference website can be found at: bps.org.uk/ac2011/ . The conference's Twitter voice is: @BPSConference According to the website, the conference's themes this year are: Development, Learning and Education Psychology, the Law and Justice Psychologists and Neuroscience

Upcoming Event: International Neuropsychological Society (2-5 February 2011, Boston)

The 39th Annual Meeting of the International Neuropsychological Society takes place in early February in Boston. Here is the conference website with basic information about the event: click here Highlights include the following keynotes, as well as a robust continuing-education program: Presidential Address: Stephen Rao, PhD Strategies for Preclinical Detection and Prevention of Alzheimer’s Disease Herbert Birch Lecture: Valerie Reyna, PhD The Neurodevelopment of Memory and Decision Making: A Fuzzy-Trace Theory Approach I am looking forward, as well, to Suzanne Corkin, PhD's Invited Lecture, Lasting Traces: How H.M. Shaped the Science of Memory